EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

Population Pharmacokinetic Modeling Practice of Time‐Varying Clearance: Insights from a First‐in‐Human Study Case

Yongjun Hu iD, Lan Gao, Ronald Kong iD

The Journal of Clinical Pharmacology · 2026-03 · 66 (3)

DOI: 10.1002/jcph.70171 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 03.03.2026. Verfasst von Yongjun Hu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmametrics in Clinical Pharmacology, PTC Therapeutics Inc., 500 Warren Corporate Center Drive, Warren, New Jersey, USA. Hauptthemen laut MEDLINE: Metabolic Clearance Rate, Models, Biological. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: PTC Therapeutics, Inc, PTC Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurate characterization of time‐varying clearance (CL) is critical during early drug development, as it informs clinical study design and dosing strategies for future trials. However, detecting and modeling time‐varying clearance is challenging due to limited data availability in early clinical development. Using pharmacokinetic data from a well‐controlled first‐in‐human (FIH) study with single and multiple ascending doses, this study explored time‐varying clearance, dose proportionality, and meal effects on pharmacokinetics (PK) of utreloxastat. Initial data analysis revealed time‐varying systemic clearance, more‐than‐dose‐proportional kinetics, and meal‐dependent PK alterations, which informed the development of a population pharmacokinetic (PopPK) model. A systematic evaluation of twelve distinct time‐varying clearance models identified an exponential time‐varying clearance model within a two‐compartment framework, incorporating first‐order absorption with eight transit compartments, as the best fit to the data. Covariate analysis confirmed that sex, age, and body weight were not significant predictors of variability. This study is the first to showcase a comparative evaluation of time‐varying clearance for a small molecule. It highlights the innovative application of time‐varying clearance modeling during the FIH study as a pivotal step in optimizing model‐informed dosing strategies. This approach underscores its importance in addressing non‐linear pharmacokinetics and enhancing drug development practices for future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic Clearance RateModels, BiologicalAdultFemaleHumansMaleMiddle AgedYoung AdultDose-Response Relationship, Drug

Stichwörter der Autor:innen

first‐in‐human (FIH) studypopulation pharmacokinetic (PopPK) modelingtime‐varying clearance

Autor:innen und Institutionen

  • Pharmametrics in Clinical Pharmacology, PTC Therapeutics Inc., 500 Warren Corporate Center Drive, Warren, New Jersey, USA.

ORCID-Profile: Yongjun Hu, Ronald Kong

Förderung

  • PTC Therapeutics, Inc
  • PTC Therapeutics

Zitieren

APA

Hu, Y., Gao, L., & Kong, R. (2026). Population Pharmacokinetic Modeling Practice of Time‐Varying Clearance: Insights from a First‐in‐Human Study Case. The Journal of Clinical Pharmacology, 66(3). https://doi.org/10.1002/jcph.70171

Vancouver

Hu Y, Gao L, Kong R. Population Pharmacokinetic Modeling Practice of Time‐Varying Clearance: Insights from a First‐in‐Human Study Case. The Journal of Clinical Pharmacology. 2026;66(3). doi:10.1002/jcph.70171

BibTeX
@article{Hu2026,
  author = {Hu, Yongjun and Gao, Lan and Kong, Ronald},
  title = {Population Pharmacokinetic Modeling Practice of Time‐Varying Clearance: Insights from a First‐in‐Human Study Case},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {3},
  doi = {10.1002/jcph.70171}
}
Kostenlos starten →